SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kirk JH, Ansell BA, Bywaters EG. The hypermobility syndrome. Ann Rheum Dis 1967; 26: 41925.
  • 2
    Grahame R. Time to take hypermobility seriously (in adults and children) [editorial]. Rheumatology (Oxford) 2001; 40: 48591.
  • 3
    Mishra MB, Ryan P, Atkinson P, Taylor H, Bell J, Calver D, et al. Extra-articular features of benign joint hypermobility syndrome. Br J Rheumatol 1996; 35: 8616.
  • 4
    Grahame R. Joint hypermobility and genetic collagen disorders: are they related? Arch Dis Child 1999; 80: 18891.
  • 5
    Al-Rawi ZS, Al-Aszawi AJ, Al-Chalabi T. Joint mobility among university students in Iraq. Br J Rheumatol 1985; 24: 32631.
  • 6
    Larsson LG, Baum J, Mudholkar GS, Srivastava DK. Hypermobility prevalence and features in Swedish population. Br J Rheumatol 1993; 32: 1169.
  • 7
    Beighton PH, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis 1973; 32: 4138.
  • 8
    Pyeritz RE. Ehlers-Danlos syndrome. In: GoldmanL, BennettJC, editors. Cecil textbook of medicine. 21st ed. Vol. 1. Philadelphia: W.B. Saunders; 2000. p. 111920.
  • 9
    Pyeritz RE. Heritable disorders of connective tissue. Primer on Rheumatic Diseases 2001; 12: 48392.
  • 10
    Grahame R, Bird HA, Child A. The British Society for Rheumatology Special Interest Group on Heritable Disorders of Connective Tissue criteria for the benign joint hypermobility syndrome: the revised (Brighton 1998) criteria for the diagnosis of BJHS. J Rheumatol 2000; 27: 17779.
  • 11
    Guma M, Olive A, Holgado S, Casado E, Roca J, Forcada J, et al. Una estimación de la laxitud articular en la consulta externa. Rev Esp Reumatol 2001; 28: 298300.
  • 12
    Bravo JF. Importancia de la hipermovilidad articular como causa frecuente de morbilidad, no sólo músculo-esquelética, sino también sistémica: criterios diagnósticos. Reumatologia 2003; 19: 338.
  • 13
    Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000; 342: 67380.
  • 14
    De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996; 62: 41726.
  • 15
    Bulbena A, Duro JC, Mateo A, Porta M, Vallejo J. Joint hypermobility syndrome and anxiety disorders. Lancet 1988; 2: 694.
  • 16
    Bulbena A, Agullo A, Pailhez G, Martin-Santos R, Porta M, Guitart J, et al. Is joint hypermobility related to anxiety in a nonclinical population also? Psychosomatics 2004; 45: 4327.
  • 17
    Pope FM, Martin GR, Lichtenstein JR, Penttinen R, Gerson B, Rowe DW, et al. Patients with Ehlers-Danlos type IV lack type III collagen. Proc Natl Acad Sci U S A 1975; 72: 13146.
  • 18
    Beighton P, DePaepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1977. Am J Med Genet 1998; 77: 317.
  • 19
    Byers P. Osteogenesis imperfecta. In: RoyceP, SteimannB, editors. Connective tissue and its heritable disorders. New York: Wiley-Liss and Sons; 1993. p. 31750.
  • 20
    Keer R, Grahame R. Hypermobility syndrome: recognition and management for physiotherapists. New York: Butterworth Heinemann Health; 2003.
  • 21
    Bravo JF. Importancia del estudio de los chilenos de alta estatura: estudio comparativo de 33 marfanoides y 230 casos de síndrome de hiperlaxitud articular [abstract]. Reumatologia 2004; 20: 218.
  • 22
    Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M, et al. Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet 2003; 73: 2147.
  • 23
    Zweers MC, van Vlijmen-Willems IM, van Kuppevelt TH, Mecham RP, Steijlen PM, Bristow J, et al. Deficiency of tenascin-x causes abnormalities in dermal elastic fiber morphology. J Invest Dermatol 2004; 122: 88591.
  • 24
    Zweers MC, Hakim AJ, Grahame R, Schalkwijk J. Joint hypermobility syndromes: the pathophysiologic role of tenascin-x gene defects [review]. Arthritis Rheum 2004; 50: 27429.
  • 25
    Bravo JF. Síndrome de hipermovilidad articular (SHA): como diferenciarlo de las otras alteraciones hereditarias de la fibra colágena. Reumatologia 2004; 20: 2430.
  • 26
    Bravo JF. Reasons to think that the lack of folic acid during the periconceptional period could be an etiological factor for the joint hypermobility syndrome. URL: www.reumatologia-dr-bravo.cl.
  • 27
    Nitsche F, Alliende M, Santos JL, Perez F, Santa Maria L, Hertrampf E, et al. Frecuencia del polimorfismo C677T de la 5, 10-metilentetradehidrofolato reductasa (MTHFR) en mujeres chilenas madres de afectados con espina bífida y en controles normales. Rev Med Chil 2003; 131: 1399404.
  • 28
    Gutierrez Revilla JI, Perez Hernandez F, Calvo Martin MT, Tamparillas Salvador M, Garcia Romero J. Polimorfismos C677T y A1298C de la MTHFR, en la etiología de los defectos del tubo neural en la población española. Med Clin (Barc) 2003; 120: 4415.
  • 29
    Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62: 125860.
  • 30
    Lucock M. Is folic acid the ultimate functional food component for disease prevention? BMJ 2004; 328: 2114.
  • 31
    McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 20429.
  • 32
    Van Meurs J, Dhonukshe-Rutten R, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 203341.
  • 33
    Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke. JAMA 2005; 293: 10828.
  • 34
    Bravo JF. Personal rheumatology. URL: www.reumatologia-dr-bravo.cl.
  • 35
    Bravo JF, Arteaga MP, Coello L. Utilidad de la cintigrafía ósea en el estudio de las alteraciones hereditarias de la fibra colágena (AHFC). URL: www.alasbimnjournal.cl/revistas/22/bravo_esp.html.
  • 36
    El-Shahaly HA, el Sherif AK. Is the benign joint hypermobility syndrome so benign? Clin Rheumatol 1991; 10: 3027.
  • 37
    Rotes J. Reumatología Clínica. Barcelona: Espaxs; 1983.
  • 38
    Bulbena A, Duro JC, Porta M, Faus S, Allescar R, Martin-Santos R. Clinical assessment of hypermobility of joints: assembling criteria. J Rheumatol 1992; 19: 11522.
  • 39
    Bridges AJ, Smith E, Reid J. Joint hypermobility in adults referred to rheumatology clinics. Ann Rheum Dis 1992; 51: 7936.
  • 40
    Grahame R. Clinical conundrum: how often, when and how does joint hypermobility lead to osteoarthritis? Br J Rheumatol 1989; 28: 320.
  • 41
    Kraus VB, Li YJ, Martin ER, Jordan JM, Renner JB, Doherty M, et al. Articular hypermobility is a protective factor for hand osteoarthritis. Arthritis Rheum 2004; 50: 217883.
  • 42
    Lahrmann H, Magnifico F, Haensch CA, Cortelli P. Autonomic nervous system laboratories: a European survey. Eur J Neurol 2005; 12: 3759.
  • 43
    Nelly WN. Upright tilt table test: internal medicine textbook. 3rd ed. Philadelphia: Lippincott-Raven; 1997. p. 349.
  • 44
    Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr 1999; 135: 4949.
  • 45
    Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003; 115: 3340.
  • 46
    Kovacs L, Paprika D, Takacs R, Kardos A, Varkonyi TT, Lengyel C, et al. Cardiovascular autonomic dysfunction in primary Sjögren's syndrome. Rheumatology (Oxford) 2004; 43: 959.